

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

ZAUDERER *et al.*

Appl. No.: 09/987,456

Filed: November 14, 2001

For: ***In Vitro* Methods of Producing and
Identifying Immunoglobulin
Molecules in Eukaryotic Cells**

Confirmation No.: 6770

Art Unit: 1639

Examiner: EPPERSON, Jon D.

Atty. Docket: 1821.0070004/EJH/T-M

**Twelfth Supplemental Information Disclosure Statement
Under 37 C.F.R. § 1.97(d)**

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on the accompanying IDS Form PTO/SB/08B is a document that may be considered material to the patentability of this application as defined in 37 C.F.R. §1.56, and in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.97 and 1.98. The numbering on this Twelfth Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Eleventh Information Disclosure Statement filed on December 3, 2007, in connection with the above-captioned application.

Applicants submit herewith as Document **NPL12** a copy of an Office Action from the related co-pending U.S. Patent Application No. 10/465,808.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Form based on

information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed after the mailing date of the a Final Rejection. Submitted electronically herewith is our credit card payment in the amount of \$180.00 for the fee under 37 C.F.R. § 1.17(p).

Statement under 37 C.F.R. § 1.97(e)(2). I hereby state that, to my knowledge after making reasonable inquiry, no item of information in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Tracy L. Muller
Attorney for Applicants
Registration No. 55,472

Date: May 21, 2008

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600
821144v1